Patents by Inventor Austin Gurney

Austin Gurney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Diagnosing and Treating Cancer
    Publication number: 20190060453
    Abstract: An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.
    Type: Application
    Filed: August 24, 2018
    Publication date: February 28, 2019
    Inventors: Austin GURNEY, Fumiko AXELROD, Tim HOEY, Sanjeev SATYAL
  • Compositions and Methods for Diagnosing and Treating Cancer
    Publication number: 20180094040
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.
    Type: Application
    Filed: July 7, 2017
    Publication date: April 5, 2018
    Inventors: AUSTIN GURNEY, John LEWICKI, Sanjeev H. SATYAL, Timothy HOEY
  • Compositions and methods for diagnosing and treating cancer
    Patent number: 9850311
    Abstract: An isolated antibody that specifically binds to an extracellular domain of two or more human FZD receptors and inhibits growth of tumor cells is described. Also described is a method of treating cancer comprising administering an antibody of the present disclosure in an amount effective to inhibit tumor cell growth.
    Type: Grant
    Filed: October 31, 2006
    Date of Patent: December 26, 2017
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin Gurney, John Lewicki, Sanjeev Satyal, Timothy Hoey
  • Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor
    Patent number: 9732139
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: August 15, 2017
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin Gurney, John Lewicki, Sanjeev H. Satyal, Timothy Hoey
  • Compositions and methods for diagnosing and treating cancer
    Patent number: 9617340
    Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: April 11, 2017
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin Gurney, Aaron Ken Sato, Maureen Fitch-Bruhns
  • Compositions and Methods for Diagnosing and Treating Cancer
    Publication number: 20160367667
    Abstract: An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 22, 2016
    Inventors: Austin GURNEY, Fumiko AXELROD, Tim HOEY, Sanjeev SATYAL
  • Compositions and Methods for Diagnosing and Treating Cancer
    Publication number: 20160185838
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.
    Type: Application
    Filed: November 30, 2015
    Publication date: June 30, 2016
    Inventors: Austin GURNEY, John Lewicki, Sanjeev H. Satyal, Timothy Hoey
  • Compositions and methods for diagnosing and treating cancer
    Patent number: 9376497
    Abstract: An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: June 28, 2016
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin Gurney, Fumiko Axelrod, Tim Hoey, Sanjeev Satyal
  • Methods of using the FRI domain of human frizzled receptor for inhibiting Wnt signaling in a tumor or tumor cell
    Patent number: 9228013
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: January 5, 2016
    Assignee: OncoMed Pharmaceuticals
    Inventors: Austin Gurney, John Lewicki, Sanjeev Satyal, Timothy Hoey
  • COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
    Publication number: 20150183878
    Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.
    Type: Application
    Filed: November 21, 2014
    Publication date: July 2, 2015
    Inventors: Austin GURNEY, Aaron Ken Sato, Maureen Fitch-Bruhns
  • Compositions and Methods for Diagnosing and Treating Cancer
    Publication number: 20140349399
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.
    Type: Application
    Filed: May 1, 2014
    Publication date: November 27, 2014
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin GURNEY, John Lewicki, Sanjeev Satyal, Timothy Hoey
  • Compositions and methods for treating and diagnosing cancer
    Patent number: 8883736
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cells. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: November 11, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventor: Austin Gurney
  • NUCLEIC ACIDS ENCODING RECEPTOR FOR IL-17 HOMOLOGOUS POLYPEPTIDES AND USES THEREOF
    Publication number: 20140323706
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: March 25, 2013
    Publication date: October 30, 2014
    Applicant: GENENTECH, INC.
    Inventors: Jian Chen, Ellen Filvaroff, Sherman Fong, Audrey Goddard, Paul Godowski, Christopher Grimaldi, Austin Gurney, Hanzhong Li, Kenneth Hillan, Daniel Tumas, Menno VanLookeren, Richard Vandlen, Colin Watanabe, P. Mickey Williams, William I. Wood, Daniel Yansura
  • Compositions and methods for diagnosing and treating cancer
    Patent number: 8802103
    Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: August 12, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin Gurney, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
  • Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1
    Patent number: 8784811
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: July 22, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: John A. Lewicki, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • Compositions and Methods for Diagnosing and Treating Cancer
    Publication number: 20140186342
    Abstract: An isolated antibody that specifically binds to an extracellular domain of human DDR2 and has a therapeutic effect on a solid tumor is described. Also described is a method of treating cancer, the method comprising administering to a patient having a solid tumor an antibody of the present disclosure in a therapeutically effective amount.
    Type: Application
    Filed: January 6, 2014
    Publication date: July 3, 2014
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: John LEWICKI, Austin Gurney, Sanjeev Satyal
  • Compositions and methods for diagnosing and treating cancer
    Patent number: 8652472
    Abstract: An isolated antibody that specifically binds to an extracellular domain of human DDR2 and has a therapeutic effect on a solid tumor is described. Also described is a method of treating cancer, the method comprising administering to a patient having a solid tumor an antibody of the present disclosure in a therapeutically effective amount.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: February 18, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: John Lewicki, Austin Gurney, Sanjeev Satyal
  • COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER
    Publication number: 20140030786
    Abstract: The present invention relates to compositions and methods for characterizing, treating and diagnosing cancer. In particular, the present invention provides a cancer stem cell profile, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of cancer and in particular the targeting of solid tumor stem cells.
    Type: Application
    Filed: July 11, 2013
    Publication date: January 30, 2014
    Applicant: The Regents of the University of Michigan
    Inventors: Michael F. Clarke, Tim Hoey, Xinhao Wang, Scott Dylla, Austin Gurney, Piero Dalerba, Grace Chen, Mark Prince
  • Compositions and methods for treating and diagnosing cancer
    Patent number: 8628774
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: January 14, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin Gurney, Aaron K. Sato
  • Compositions and Methods for Treating and Diagnosing Cancer
    Publication number: 20130336970
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cells. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
    Type: Application
    Filed: March 13, 2013
    Publication date: December 19, 2013
    Inventor: AUSTIN GURNEY